Study protocol for a randomised double-blinded, sham-controlled, prospective, cross-over clinical trial of vagal neuromodulation for pain treatment in patients with chronic pancreatitis by Muthulingam, Janusiya Anajan et al.
 
  
 
Aalborg Universitet
Study protocol for a randomised double-blinded, sham-controlled, prospective, cross-
over clinical trial of vagal neuromodulation for pain treatment in patients with chronic
pancreatitis
Muthulingam, Janusiya Anajan; Olesen, Søren Schou; Hansen, Tine Maria; Brock, Christina;
Drewes, Asbjørn Mohr; Frøkjær, Jens Brøndum
Published in:
BMJ Open
DOI (link to publication from Publisher):
10.1136/bmjopen-2019-029546
Creative Commons License
CC BY-NC 4.0
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Muthulingam, J. A., Olesen, S. S., Hansen, T. M., Brock, C., Drewes, A. M., & Frøkjær, J. B. (2019). Study
protocol for a randomised double-blinded, sham-controlled, prospective, cross-over clinical trial of vagal
neuromodulation for pain treatment in patients with chronic pancreatitis. BMJ Open, 9(7), 1-9. [e029546].
https://doi.org/10.1136/bmjopen-2019-029546
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
1Muthulingam JA, et al. BMJ Open 2019;9:e029546. doi:10.1136/bmjopen-2019-029546
Open access 
Study protocol for a randomised 
double-blinded, sham-controlled, 
prospective, cross-over clinical trial of 
vagal neuromodulation for pain 
treatment in patients with 
chronic pancreatitis
Janusiya Anajan Muthulingam,1,2 Søren Schou Olesen,2,3 Tine Maria Hansen,1,2 
Christina Brock,2,4 Asbjørn Mohr Drewes,2,3 Jens Brøndum Frøkjær  1,2
To cite: Muthulingam JA, 
Olesen SS, Hansen TM, 
et al.  Study protocol for a 
randomised double-blinded, 
sham-controlled, prospective, 
cross-over clinical trial of 
vagal neuromodulation for 
pain treatment in patients with 
chronic pancreatitis. BMJ Open 
2019;9:e029546. doi:10.1136/
bmjopen-2019-029546
 ► Prepublication history for 
this paper is available online. 
To view these files please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
029546). 
Received 31 January 2019
Revised 4 June 2019
Accepted 21 June 2019
For numbered affiliations see 
end of article.
Correspondence to
Professor Jens 
Brøndum Frøkjær;  jebf@ rn. dk
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction The management of chronic pancreatitis 
(CP) is challenging and requires a personalised approach 
focused on the individual patient’s main symptoms. 
Abdominal pain is the most prominent symptom in CP, 
where central pain mechanisms, including sensitisation 
and impaired pain modulation, often are involved. Recent 
clinical studies suggest that vagal nerve stimulation (VNS) 
induces analgesic effects through the modulation of 
central pain pathways. This study aims to investigate the 
effect of 2 weeks transcutaneous VNS (t-VNS) on clinical 
pain in patients with CP, in comparison to the effect of 
sham treatment.
Methods and analysis Twenty-one patients with CP will 
be enrolled in this randomised, double-blinded, single-
centre, sham-controlled, cross-over study. The study 
has two treatment periods: A 2-week active t-VNS using 
GammaCore device and a 2-week treatment with a sham 
device. During both treatment periods, the patients are 
instructed to self-administer VNS bilaterally to the cervical 
vagal area, three times per day. Treatment periods will be 
separated by 2 weeks. During the study period, patients 
will record their daily pain experience in a diary (primary 
clinical endpoint). In addition, all subjects will undergo 
testing which will include MRI, quantitative sensory 
testing, cardiac vagal tone assessment and collecting 
blood samples, before and after the two treatments to 
investigate mechanisms underlying VNS effects. The data 
will be analysed using the principle of intention to treat.
Ethics and dissemination The regional ethics committee 
has approved the study: N-20170023. Results of the trial 
will be submitted for publication in peer-reviewed journals.
trial registration number The study is registered at 
www. clinicaltrials. gov: NCT03357029.
IntroduCtIon
Chronic pancreatitis (CP) is a disease charac-
terised by progressive pancreatic inflamma-
tion and fibrosis, resulting in damage to and 
loss of exocrine (acinar), endocrine (islet 
cells) and ductal cells.1 Chronic abdominal 
pain is the dominating symptom in CP and is 
present in up to 70% of patients.2 Pain is asso-
ciated with reduced quality of life, increased 
hospitalisation frequencies and thus a signifi-
cant socioeconomic burden.3 
The aetiology of pain in CP is increas-
ingly better understood and often involves 
multiple mechanisms in the individual 
patient. In addition to local pathology in the 
pancreatic gland and its surrounding tissues, 
central pain pathways undergo neuroplastic 
changes during the course of CP. These 
involve sensitisation of central pain path-
ways, functional and structural reorganisa-
tion of the brain as well as impaired efficacy 
of endogenous pain modulatory pathways. 
These neural abnormalities can be targeted 
by different pharmacological therapies, but 
their effect is often limited and associated 
with significant side-effects in many patients. 
strengths and limitations of the study
 ► This is the first study to examine the analgesic effect 
of transcutaneous vagal nerve stimulation (t-VNS) in 
patients with chronic pancreatitis with abdominal 
pain.
 ► A randomised double-blinded, sham-controlled, pro-
spective cross-over design will be used with both 
clinical and experimental outcomes, which allow for 
the exploration of the mechanisms underlying puta-
tive clinical effects.
 ► The study investigates the effect of 2 weeks of t-VNS 
treatment; hence, further studies are needed to ex-
plore long-term effects.
 ► The single-centre design may limit generalisability 
of the study results.
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This has led to an increased interest in complementary 
treatment modalities for pain in patients with CP. In a 
model of oesophageal hyperalgesia, we have shown that 
physiological deep breathing enhanced vagal tone, which 
in response increased the pain detection threshold.4 In 
addition, this effect was abolished by atropine adminis-
tration thereby proving that enhanced parasympathetic 
tone leads to the prevention of oesophageal pain hyper-
sensitivity.4 Also, we have previously shown an improved 
gastrointestinal motility and decreased pain sensitivity 
following non-invasive vagal nerve stimulation (VNS) of 
the auricular branch of the vagal nerve in conjunction 
with a deep-breathing approach in healthy subjects.5 
Another non-pharmacological treatment modality is 
transcutaneous vagal nerve stimulation (t-VNS), in which 
short bursts of electrical energy are directed onto the 
vagal nerve at the neck6 (figure 1). t-VNS has been shown 
to induce analgesic5 7 and anti-inflammatory effects in 
healthy individuals8 and different diseases. The exact 
mechanisms by which VNS modulates chronic pain are 
unclear; however, it has been proposed that the anal-
gesic effect is potentially mediated by vagal afferents that 
inhibit spinal nociceptive reflexes and transmission.9 
Specifically, the analgesic effects are mediated through 
vagal afferent modulation in the nucleus tractus soli-
taries, raphe magnus, locus ceruleus, amygdala and peri-
aqueductal grey, which are involved in the descending 
inhibition of pain.9 10 It has also been demonstrated that 
VNS inhibits spinal cord neurons below C3 but excites 
neurons between C1 and C3, suggesting that proprio-
spinal neurons from high segments play an essential role 
in vagally mediated antinociception. Thus, VNS appears 
to induce neuromodulatory antinociception through 
peripheral and central, ascending and descending 
pathways.11 Also, the non-pharmacological treatment is 
FDA approved for the acute treatment in patients with 
migraine.12
This study aims to examine the analgesic effect of a 
2-week t-VNS in patients with CP and to explore the 
underlying analgesic mechanisms using advanced neuro-
imaging techniques and quantitative sensory testing 
(QST). We hypothesised that 2-week t-VNS treatment 
will induce clinically relevant pain relief compared with 
sham treatment, and that these effects are mediated via 
the modulation of central pain pathways. To answer the 
overall study aims, we have two clinical and two experi-
mental objectives:
1. The primary clinical objective is to assess the effect of 
t-VNS on the daily pain experience documented in a 
pain diary in patients with CP.
2. Secondary clinical objectives are to document changes 
in quality of life and daily functioning.
3. The experimental objective is to assess the effect of 
t-VNS on (A) resting state brain function assessed by 
MRI, and (B) brain metabolites assessed by magnetic 
resonance spectroscopy.
4. Secondary experimental objectives are to assess the 
effect of t-VNS on (A) experimental pain stimuli doc-
umented by QST, (B) cardiac vagal tone (CVT) and 
(C) proinflammatory cytokine profiles obtained from 
blood samples.
MEthods And AnAlysEs
study design
Randomised, single-centre, double-blinded, prospec-
tive, sham-controlled, cross-over study. The trial will be 
performed at Aalborg University Hospital and will be 
reported according to the Consolidated Standards of 
Reporting Trials.13 The study protocol follows the Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials statement.14
All patients undertake the t-VNS treatment using an 
active GammaCore-S, 300 treatments (10 009-00603) 
device (ElectroCore LLC, Basking Ridge, New Jersey, 
USA) and sham treatment using a sham device (10009-
00603 P) which is identical in appearance to GammaCore.
Half of the patients will be randomised to start with 
2-week t-VNS treatment, followed by a 2-week washout 
period. Then, this group will be reallocated to sham 
treatment. The other half of patients will do the study 
periods in opposite order (sham treatment followed by 
t-VNS treatment). The 2-week washout period has been 
used in the previous studies of transcranial neuromodu-
lation15 and was shown to be sufficient to reset the effects 
of neuromodulation.16 Each patient will be scheduled 
for four identical hospital visits (before and after each 
treatment period). The visits consist of (1) fulfilment of 
questionnaires, (2) collection of blood samples, (3) brain 
Figure 1 Mode of action of transcutaneous vagal 
nerve stimulation (t-VNS). (1) Pain arises in the periphery, 
for example, pancreas and a signal is sent to the spinal cord. 
This leads to the ascending activation of the spinal neurons 
(2). In the brain, pain is processed in higher cortical centres 
(3). t-VNS, it is expected to block the perception of pain in 
the cerebral cortex, by stimulating nucleus tractus solitarius 
and thereby decrease glutamate level. Simultaneously, the 
net-descending inhibition will be activated as a result of top-
down input from cortex and the limbic system (4).
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MRI scan, (4) QST and (5) assessment of CVT (figure 2, 
table 1).
study participants
Patients will be recruited via personal correspondence 
and during visits at the outpatient clinic. Patients who 
agree to participate in the study and fill in an informed 
consent will be invited to participate in the study. A 
screening session and physical examination prior to 
inclusion will be conducted by a medical doctor including 
relevant medical and medication history and screening 
against the eligibility criteria. All patients will be asked to 
continue their medication during the entire study, and 
any changes needed in pain medication will be noted in 
the diary.
Inclusion criteria and exclusion criteria
Patients from the age of 18 years will be included in the 
study. They will have a clinical diagnosis of CP based on 
the Mayo clinical diagnostic criteria.17 All aetiological 
types of patients with CP would be included (including 
alcohol, nicotine, hereditary, efferent duct factors and 
immunological aetiologies). The patients must suffer 
from chronic abdominal pain characteristics for CP, meet 
the criteria for chronic pain (pain ≥3 days per week for at 
least 3 months) and must consider their pain as insuffi-
ciently treated with their prescribed analgesic treatment. 
Additionally, the patients must be willing and able to 
comply with the scheduled visits, treatment plan, labora-
tory tests and other study procedures. Finally, the patient 
must sign the informed consent and power of attorney 
document.
Patients will be excluded if they have any clinically signif-
icant abnormalities that may increase the risk associated 
with trial participation or may interfere with the inter-
pretation of the trial results. Also, patients with alcohol 
and illegal drug dependence, cardiovascular diseases, low 
blood pressure (<100/60 mm Hg), elevated intracranial 
pressure will be excluded. Additionally, patients who are 
participating in another intervention study, patients who 
are pregnant or intend to become pregnant and patients 
who suffer from painful conditions other than CP that 
make them unable to distinguish the pain associated with 
CP from chronic pain of other origin will be excluded. 
Patients will also be excluded if there are any contraindi-
cations for MRI (including cardiac pacemaker, implant-
able metallic components, etc.), have known neuropathy 
or previous vagal nerve surgery (table 1).
Participants can withdraw from the study at any time 
they may wish. Patients will be withdrawn from the study 
if they do not meet for the scheduled study visits or miss a 
treatment period, and if they do not maintain inclusion/
exclusion criteria.
Interventions
Study interventions are t-VNS treatment and sham treat-
ment (figures 2 and 3). Prior to receiving the t-VNS treat-
ment/sham treatment, the standard care must be stable.
Patients will be thoroughly instructed to use the device, 
and when the healthcare providers are confident that 
the patient is capable of using the device independently, 
the device will be handed over to the patient. t-VNS is 
administered by using a handheld device (GammaCore; 
ElectroCore LLC), which consists of a battery-powered 
portable stimulator with a digitally controlled user inter-
face that controls the signal amplitude and two gel-cov-
ered (Sigma gel, Parker Laboratories, New Jersey, USA) 
contact electrodes which deliver electrical stimulation to 
the cervical vagal nerve. One dose corresponds to 120 s 
of t-VNS to the left cervical vagal nerve followed by 120 s 
of t-VNS to the right cervical vagal nerve, with the ampli-
tude of simulation titrated to achieve mild pulling of the 
ipsilateral oral commissure.18 Bilateral stimulation has 
shown to be effective in previous studies with Gamma-
Core.19 20 The patient self-administers the treatment, 
using the device at home three times per day (morning, 
afternoon and evening) for 2 weeks. Previous studies with 
Gamma-Core have shown that three doses per day have 
been effective.12 21
Figure 2 Schematic flow chart of the interventional study 
design enabling comparison of the modulatory effect to 
self-administered of transcutaneous vagal nerve stimulation 
(t-VNS) in patients with chronic pancreatitis. Patients with 
chronic pancreatitis will be randomly assigned to one of two 
double-blinded treatments: (1) 2 weeks of t-VNS, 2 weeks 
of washout and 2 weeks of sham treatment; or (2) 2 weeks 
of sham treatment, 2 weeks of washout and 2 weeks of 
t-VNS. Evaluation of the two treatments will be assessed by 
collecting pain diary, pain questionnaires, MRI scan, blood 
sample, cardiac vagal tone (CVT) and pain assessments. 
quantitative sensory testing (QST).
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The stimulation device is positioned anterior to the 
sternocleidomastoid muscle, over the carotid artery 
as this runs in close proximity with the vagal nerve. 
The active GammaCore device produces a low-voltage 
electrical signal comprising a 5 kHz sine wave burst lasting 
for 1 ms (five sine waves, each lasting 0.2 ms), with such 
bursts repeated once every 40 ms (25 Hz), generating a 
24 V peak voltage and 60 mA peak output current. Those 
Table 1 Trial characteristics based on WHO trial registration dataset
Data category Trial information
Primary registry and trial 
identifying number
ClinicalTrials.gov (NCT03357029)
Date of registration in 
primary registry
29 November 2017
Secondary identifying 
numbers
North Denmark Region Committee on Health Research Ethics: protocol number N-20170023
Source(s) of monetary or 
material support
The study is conducted as a sponsor–investigator initiated study with financial support from 
Independent Research Fund Denmark (DFF: 7016-00073).
Primary sponsor JBF
Secondary sponsor NA
Contact for public queries JBF
Contact for scientific 
queries
JBF
Public title Neuromodulation in patients with painful chronic pancreatitis (CP)
Scientific title Study protocol for a randomised double-blinded, sham-controlled, prospective, cross-over clinical 
trial of vagal neuromodulation for pain treatment in patients with CP
Country of recruitment Denmark
Healthy conditions(s) or 
problems studied
CP
Interventions 2-week transcutaneous vagal nerve stimulation (t-VNS) on the cervical vagal area (self-
administering vagal nerve stimulation bilaterally to the cervical vagal area, the times per day).
Key inclusion and 
exclusion criteria
Inclusion criteria: age≥18 years; patients with a diagnosis of CP diagnosed using the Mayo Clinic 
diagnostic criteria; the participants must be able to read and understand Danish; the patients 
must suffer from chronic abdominal pain characteristic for CP, meet the criteria for chronic pain 
(pain≥3 days per week in at least 3 months) and must consider their pain as insufficiently treated 
with their usual analgesic treatment; personally, signed and dated informed consent document 
and the power of attorney document; patients willing and able to comply with the scheduled 
visits, treatment plan, laboratory tests and other trial procedures. Exclusion criteria: patients with 
any clinically significant abnormalities that in the opinion of the investigator may increase the risk 
associated with trial participation or may interfere with the interpretation of the trial results; alcohol 
dependence; illegal drug dependencies; participating in another study where investigational drug 
is used; patients must not suffer from painful conditions other than CP that make them unable 
to distinguish the pain associated with CP from the chronic pain of other origin; cardiovascular 
diseases; low blood pressure<100/60, not able to understand or follow the instructions; any 
condition with elevated intracranial pressure; female patients who are pregnant; contraindications 
for MRI; previous surgery on vagal nerve; known neuropathy.
Study type Interventional allocation: randomised
Masking: double blind
Assignment: crossover
Primary purpose: treatment
Date of first enrolment January 2018
Target sample size 21
Recruitment status Recruiting
Primary outcome(s) Change in NRS scores in pain diary
Key secondary outcomes 
(s)
Assessment of the effect of t-VNS on (A) resting state brain function assessed by MRI, and (B) 
brain metabolites assessed by MR spectroscopy.
DFF, Danmarks Frie Forskningsfond (Independent Research Fund Denmark); MR, magnetic resonance; NRS, Numeric Rating Scale. 
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parameters have been used to activate the vagal nerve in 
electrophysiological studies.19 20
To mimic the sensation of the active treatment, the 
sham device will provide vibration.22 The appearance, 
weight, visual and audible feedback, and user application 
are identical for the sham and t-VNS devices. However, 
the sham device produces a low-frequency (0.1 Hz) 
biphasic signal that does not stimulate the vagal nerve or 
generally cause muscle contractions.23 Additionally, both 
devices will display a numeric value between 1 and 40, 
signifying the intensity of the stimulation. The maximum 
intensity per stimulation is 40 for both devices (figure 1). 
The intensity of the stimulation can vary from patient 
to patient. The intensity for stimulation is reached by 
increasing the stimulation to the maximum which the 
patient can tolerate without excessive pain. Some patients 
can tolerate less than other patients depending on the 
pain level. Therefore, the dosage of every stimulation is 
patient dependent.24
Compliance will be assessed by reading the remaining 
doses displayed at the device after each treatment period. 
Additionally, the patients will be asked to keep a record 
of the stimulation intensity of the doses applied at each 
stimulation. In addition, questions on compliance will be 
asked after each treatment period. Finally, adherence will 
be recorded by patients’ diary.
During the study periods, the patient will continue 
their standard care, without changes in their current pain 
treatment.
randomisation, sequence generation and allocation 
concealment
Once eligibility and consent have been approved and 
completed, randomisation will occur using a randomi-
sation list generated by an automatic web-based rando-
misation programme. Patients will be randomly assigned 
to VNS/sham or sham/VNS using block randomisation, 
allowing seven patients at the time to be randomised in 
equal proportions for the order of active t-VNS or sham 
stimulation. The randomisation order will be kept in 
closed envelopes; therefore, patients will get their assign-
ment according to the order of entrance in the study. This 
process will be carried out by a member of the research 
team who is not involved in the recruitment process or 
conduction of the study.
An unblinded researcher will be involved in deliv-
ering the medical device according to the randomisa-
tion schedule. The sequence will follow a 1:1 sequential 
design, in a double-blinded fashion. Additionally, the 
outcome assessor (data analyst) will be blinded during 
the statistical analyses of experimental outcomes. A series 
of numbered, sealed, envelopes will be used to ensure 
concealed allocation.
blinding
Both, active and sham devices are labelled with a serial 
number and not outwardly identified as active or sham. 
All researchers involved in the data collection and MRI 
analysis will be blinded to the treatment allocation group 
until after analyses are performed at the completion of 
the trial. Additionally, all patients are blinded, and they 
do not know that the sham treatment is an inactive treat-
ment. Particularly, patients will be informed that they have 
to undergo two different interventions with two different 
devices, and the purpose of this study is to investigate the 
most effective treatment.
Manufacturing and preparation of the medical devices 
are handled by an external good manufacturing prac-
tice-accredited facility (ElectroCore). As the patients do 
not know that the sham treatment is an inactive treatment, 
we will not be able to ask the patient ‘do you think you 
received active or inactive treatment?’; thus, we will not 
be able assess and determine if the blinding was effective.
Unblinding is only permissible if a patient experiences 
any serious adverse events and that the investigator/
doctor judge that it is essential to know the treatment 
allocation in order to treat the patient appropriately.
Primary clinical outcome measures
The primary clinical efficacy parameter to be evaluated 
is 30% pain relief. This is assessed as changes in the 
daily experience of pain, which will be measured using 
a patient pain diary based on the Numeric Rating Scale 
(NRS) (1=no pain, 10=worst pain imaginable). Patients 
will be asked to score daily pain levels in the diary for 
8 weeks (including 1 week before the first treatment 
period and 1 week after the last study period, figures 2 
and 3), with one NRS value for the average pain over the 
Figure 3 Standard Protocol Items: Recommendations for 
Interventional Trials figure. BPI-SF, Brief Pain Inventory—
Short Form; CVT, cardiac vagal tone; PGIC, Patient Global 
Impression of Changes Questionnaire; QST, quantitative 
sensory testing; VNS, vagal nerve stimulation.
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previous 24 hours and one NRS value for the worst pain 
over the previous 24 hours.
secondary clinical outcome measures
Quality of Life Questionnaire, C30, V.3.0 (QoLQ-C30),25 
the Brief Pain Inventory—Short Form (BPI-SF) Ques-
tionnaire26 and Patient Global Impression of Changes27 
Questionnaire (PGIC) are secondary clinical outcomes. 
Patient will complete QoLQ-C30 and BPI-SF Question-
naire before and after each treatment period, while the 
PGIC Questionnaire will only be fulfilled after the treat-
ment periods. The QoLQ-C30 is composed of both multi-
item scales and single-item measures. These include five 
functional scales, three symptom scales, a global health 
status and six single items. The BPI-SF Questionnaire 
rapidly assesses the severity of pain and its impact on daily 
functioning. Finally, the PGIC Questionnaire evaluates all 
aspects of patients’ health and assess if there has been an 
improvement or decline in the overall clinical status.
Experimental outcome measures
Resting state functional MRI will be employed to detect 
brain activity and functional connectivity changes based 
on blood oxygen level-dependent (BOLD) signals 
before and after treatment of each patient. Additionally, 
magnetic resonance spectroscopy in anterior cingulate 
cortex, prefrontal cortex, parietal and insula will also 
be performed in order to investigate changes in brain 
metabolites before and after each treatment.
MRI data will be acquired on a 3 T MR scanner (Signa 
HDxt, General Electric, Milwaukee, Wisconsin, USA) 
equipped with an eight channel standard head coil. 
Scan time for a structural scan will be 5½ min. Following 
parameters will be used for the structural scan: 150 slices, 
field of view (FOV) 250 mm, echo time 3.6 ms, repeti-
tion time 9.0 ms, flip angle 14°, resolution 0.78×0.78 mm, 
matrix size 320×320 mm, slice thickness 1 mm, full 
head coverage, with no gap. Functional scans will be 
acquired with following parameters: gradient echo, echo 
planar imaging, 192 volumes, 37–40 slices, FOV=240 mm, 
echo time=30 ms, repletion time=2000 ms, flip angle=90°, 
matrix size=64×64, resolution=3.75×3.75 mm, slice 
thickness 3.8 mm, no gap, axial slices. The scan time 
for functional MRI will be 6 min and 32 s. Additionally, 
MRI spectroscopy will be used to estimate brain metab-
olites in the anterior cingulate cortex, prefrontal cortex, 
parietal and insula. For MRI spectroscopy, single voxel 
point resolved spectroscopy will be acquired. Following 
parameters will be used: echo time=30 ms, repetition 
time=2000 ms, scan time will be 5 min and the total 
number of scans will be 128. Bandwidth will be 5000 Hz. 
A 20×20×20 mm voxel of interest will be positioned on a 
sagittal T2-weighted fast spin echo sequence. Repletion 
time=4600 ms and echo time=102 ms, matrix 384×256, 
slice thickness 3 mm, gap 0.3 mm, in the midline in the 
anterior cingulate cortex (ACC) with the inferior border 
along the anterior–posterior commissure line.
secondary experimental outcome measures
Secondary outcomes are changes in QST, CVT and proin-
flammatory cytokine profiles.
QST includes temporal summation,28 pressure pain 
thresholds28 29 and conditioned pain modulation 
(CPM).30 Temporal summation demonstrates an increase 
perception of pain to repetitive pain stimuli.28 Temporal 
summation will be recorded in the dermatome T10 
(pancreatic area) and control area (dominant forearm) 
using the PinPrick stimulator, 256 mN (MRC Systems 
GmbH Medizintechnische Systeme, Germany).
The pressure pain threshold and pressure pain toler-
ance will be determined by pressing an electronic pres-
sure algometer (Somedic AB, Stockholm, Sweden) on 
specified muscle groups: C5—clavicula, T10—dorsum, 
T10—abdomen, L1—anterior superior iliac spine, and 
rectus femoris. Also, pressure pain threshold and pres-
sure pain tolerance will be measured on bone. For the 
muscle pressure stimulation, the probe has a surface area 
of 1 cm2. Pressure will be increased at a rate of 30 kPa/s 
until the pressure pain threshold is reached. For the bone 
pressure stimulation, a probe with 3.1 mm2 (Aalborg 
University, Denmark) will be applied.
CPM is a clinically measurable form of descending pain 
modulation30 that can be induced experimentally by a 
conditioning stimulus (the cold pressor test) and quan-
tified by applying a ‘test pain’ (pressure stimulation of 
the right quadriceps musculature) before and after its 
induction.31 The patient will lower their dominant hand 
in cold water (2°C for maximum 2 min). The difference 
in pressure stimulus intensity (pain threshold) before 
and after induction of cold pressor pain provides a quan-
titative index of CPM capacity for the individual patient. 
The techniques used for pressure stimulation and cold 
pressor test described above will be combined to measure 
CPM.
CVT is a beat-to-beat measure of brainstem efferent 
vagal activity, which is assessed by heart rate variability 
measurement and reflects the contribution of the vagal 
nerve to cardiac functioning. In this particular test, 
changes in R–R interval would be measured non-inva-
sively using eMotion Faros 180 device.32
Blood samples are collected to explore changes in 
proinflammatory cytokines profiles. 26 mL blood is 
collected, and the following inflammatory state and 
macrophage markers will be assessed: interferon-G, 
interleukin 8 (IL-8), IL-10, IL-12p70, IL-13, IL-1b, IL-2, 
IL-4, IL-6, tumour necrosis factor- α (TNF-α), monocyte 
chemoattractant protein-1 and high sensitivity C reactive 
protein.
statistical power
The study is powered to detect a minimal difference 
between the sham treatment and the active treatment 
of 30% on the average clinical pain score at the end of 
the two study periods. Based on a SD of 40%, we deter-
mine that a study with 16 patients in a cross-over design is 
needed, with a power of 80%, and the use of a two-sided 
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significance level of 0.05 (alpha). This calculation (SD) 
is based on data from a study with patients with CP, 
who received pregabalin treatment, which related to an 
improvement in clinical measures of the pain score.33 To 
allow for a dropout rate of 25%, we will aim to recruit 
21 patients with CP. The sample size was calculated using 
statistical software package STATA V.15.0 (StataCorp LP, 
College Station).34
harms and adverse events
We do not anticipate this project causing any harm or 
discomfort to the patients, and we will ensure that our 
patients participate in the study voluntarily.
Information about adverse events and serious adverse 
events will be collected from the date of inclusion and in 
all following contacts with the study subject throughout 
the project. Adverse events will be documented on the 
patient file and on the electronic case report form. All 
types of adverse events will be notified to the device manu-
facturer ElectroCore and to the Danish Health Authori-
ties by use of Manufactures Incident Report Form.
data collection and data management
All instruments in the questionnaires are validated.25 26 
Additionally, all data collectors are highly experienced 
registered research nurses, radiographers and researchers 
who have been trained in good clinical practice (GCP). 
There will be regular meetings between the data collec-
tors, monitor, principal investigator and other core-
searchers involved in the project. All paper protocols will 
be kept safe and transferred to a computerised database. 
The questionnaires will be checked for errors and missing 
data by research staff. Data entries are double checked 
against the paper questionnaires.
During trial conduct, the GCP unit (GCP, Aalborg, 
Denmark) will conduct periodic monitoring of all signed 
consents at monitoring visits to ensure that the protocol 
and GCP standards are followed. The monitors may 
review source documents and medical records to confirm 
that data recorded on case report form is accurate. Thus, 
GCP monitoring includes all signed consents, signed 
power of attorney and adverse event (AE).
Criteria for the termination of the trial are when 
patients according to the sample size with valid data are 
recorded. If the study fails to recruit adequate patients 
according to the sample size by the end of 2019, the study 
will be terminated.
data analysis
Both descriptive and analytical statistics will be used in 
order to compare groups and for analyses of outcomes 
over time including changes therein. All data will be 
presented as mean ±SD and summarised in frequency 
tables, unless otherwise indicated. We will use Research 
Electronic Data Capture (REDCap)35 to store the data 
and the statistical software package STATA to perform 
statistical analysis. We will use mixed analysis of variance 
(ANOVA) for the inferential statistic of the parametric 
data, with Tukey’s and/or Bonferroni post hoc tests for 
the primary clinical endpoints. Significance level will be 
set as α ≤0.05.
The principal analysis of clinical endpoints will be by 
intention to treat, meaning that all randomised patients 
are included in their initially assigned study arm, regard-
less of adherence to study protocol. Experimental 
endpoints will be analysed by per protocol, meaning 
that only patients completing the experimental set-up 
are included. The primary endpoints will be compared 
between the treatment groups.
Analysis of MRI data: we will use standard preprocessing 
procedures in Statistical Parametric Mapping (http://
www. fil. ion. ucl. ac. uk/ spm/) before conducting the statis-
tical analysis. Moreover, we will use a mixed effects design 
in which within-subject effects between the two treat-
ments (before and after both treatments) responses brain 
activity and group effects will be modelled. For MR spec-
troscopy, specific metabolites changes will be assessed in 
pain-related brain regions.36
The rest of the data, like demographic data, change 
in circulating cytokines, and others, will be used descrip-
tively and as input to regression and mixed-model anal-
yses. The final statistical analysis plan, providing details of 
the analysis and presentation of the results, will be final-
ised before initiating any statistical analysis.
Patient and public involvement
The study was designed based on the need for new ther-
apeutic options for patients with CP and the literature 
relating to pain management in CP, as described in the 
introduction. The outcomes, such as pain scores and MRI 
brain scans, were deliberately chosen in order to assess 
the potential effect of t-VNS treatment both subjectively 
(patient oriented) and objectively. Furthermore, no 
patients were directly involved in the design, recruitment 
to or conduct of the study. However, an expert/chief 
doctor specialised in CP disease is an associated investi-
gator of the study (SSO). The results and findings gath-
ered from this study will be provided to the patients on 
request in the form of a written report.
There was no public involvement in the study design.
dIsCussIon
To the best of our knowledge, there are no randomised, 
sham-controlled, studies investigating the effect of t-VNS 
on clinical pain in patients with CP. We expect the study 
to provide clinical evidence of the analgesic effect of VNS 
and to elucidate its underlying mechanisms of action. 
This may pave the road for non-pharmacological treat-
ment of pain associated with CP and the findings of the 
study may be generalisable to chronic pain conditions per 
se.
Previous studies have shown structural and functional 
alterations of the CNS in patients with CP with abdominal 
pain.37–41 The central nervous system (CNS) mechanisms 
may have the ability to recover by targeting treatment at 
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plasticity mechanisms and reorganisation of neuronal 
pathways leading to the improvement of clinical symp-
toms.42 VNS treatment has emerged a promising tech-
nique in stimulating neural reorganisation and synaptic 
plasticity in cortical and subcortical networks, leading 
to the modulation of serotoninergic and noradrenergic 
pain inhibitory pathways.43 Those mechanisms might 
alter and regenerate the neural connectivity in regions 
responsible for pain.44–46 In addition, the vagal nerve 
serves as an essential transmitter of inflammatory signals 
in immune-to-neuronal communication.47–49 Afferent 
fibres of the vagal nerve relay information from viscera 
to the nucleus tractus solitaries in the brainstem, where it 
‘senses’ proinflammatory cytokines such as IL-1, IL-6 and 
TNF-α. Information is then projected to the parvocellular 
zone of the paraventricular nucleus of the hypothalamus, 
and therefore the comparison of functional alterations in 
the CNS and circulating levels of proinflammatory cyto-
kines may provide evidence of an existing association. 
Some limitations about the study should be discussed. 
First, the patient group is very heterogeneous; they may 
suffer from comorbidities and may receive other pharma-
cological therapies, which may bias the results and conse-
quently makes it difficult to assess the isolated effect of 
the VNS treatment. Second, the researchers may involun-
tarily become unblinded since the active treatment will 
deliver facial contractions while this is not present during 
sham treatment. Third, the relatively low number of 
patients may hamper the results including the explorative 
secondary outcomes; however, we eliminate the inter-
individual variability because of the cross-over design. 
Finally, although all the patients will be trained to use the 
device correctly according to manufactures’ protocol, it is 
uncertain whether the patients will applicate the device 
correctly.
Regarding expected outcome, we hypothesise that 
VNS will reduce the pain in patients with CP and induce 
changes in pain-associated brain networks as well in the 
autonomic, inflammatory parameters and in the sensory 
system. Also, we expect that the neuromodulation will 
improve the overall quality of life in patients with CP.
ConsEnt to PArtICIPAtE
The procedures set out in this study protocol, pertaining 
to conduct the study in compliance with GCP (CPMP/
ICH/135/95), designated Standard Operating Proce-
dures, the Danish Health and Medicines Authority, the 
Research Ethics Committee in Denmark, and within the 
principles of the World Medical Association, Declaration 
of Helsinki amended by the 52nd General Assembly, Edin-
burgh, Scotland, October 2000, clarified by the General 
Assembly in Washington 2002, Tokyo 2004, and Seoul 
2008 and Fortaleza 2013 as outlined herein.
Investigators (ie, medical doctors) will obtain informed 
consent from each patient. We will conduct this study 
under the rules of Resolution 466/12 and Declaration 
of Helsinki. Data will be stored electronically in REDCap 
database, with secure and restricted access. Data transfer 
will be encrypted and any information capable of iden-
tifying individuals removed. Results gathered from this 
protocol will be presented at national and international 
conferences and will be published in peer-reviewed jour-
nals. All confidential patient data will be protected, and 
patient identity will not be disclosed. Further dissem-
ination of the dataset can be decided by the principal 
investigator.
Only researchers involved in the data collection and/or 
data analysis will have access to the final dataset. However, 
the principal investigator allows direct access to all source 
data and documents at monitoring, and inspection 
from the North Denmark Region Committee on Health 
Research Ethics, the Danish Health and Medicines 
Authority or from other countries’ health authorities.
trial status
The recruitment of the study started in January 2018. As 
of January 2019, a total of 13 patients have completed the 
study.
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